Technical Analysis for RLAY - Relay Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical RLAY trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | -3.37% | |
| New Downtrend | Bearish | -3.37% | |
| Lower Bollinger Band Walk | Weakness | -3.37% | |
| Inside Day | Range Contraction | -3.37% | |
| Oversold Stochastic | Weakness | -3.37% | |
| Lower Bollinger Band Walk | Weakness | -6.06% | |
| New 52 Week Low | Weakness | -6.06% | |
| Lower Bollinger Band Touch | Weakness | -6.06% | |
| Oversold Stochastic | Weakness | -6.06% | |
| New 52 Week Closing Low | Bearish | -3.72% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 2 hours ago |
| Down 3% | about 2 hours ago |
| Fell Below Lower Bollinger Band | about 2 hours ago |
| New 52 Week Low | about 2 hours ago |
| Down 2 % | about 4 hours ago |
Get a Trading Assistant
- Earnings date: ???
Relay Therapeutics, Inc. Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Drug Discovery Enzymes Precision Medicine Tyrosine Kinase Tyrosine Kinase Receptors Advanced Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Metastatic Solid Tumors Fibroblast Growth Factor Receptor 2
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 64.0 |
| 52 Week Low | 26.84 |
| Average Volume | 729,523 |
| 200-Day Moving Average | 41.22 |
| 50-Day Moving Average | 34.64 |
| 20-Day Moving Average | 31.76 |
| 10-Day Moving Average | 30.03 |
| Average True Range | 2.16 |
| ADX | 26.46 |
| +DI | 8.68 |
| -DI | 27.48 |
| Chandelier Exit (Long, 3 ATRs ) | 29.08 |
| Chandelier Exit (Short, 3 ATRs ) | 33.33 |
| Upper Bollinger Band | 36.19 |
| Lower Bollinger Band | 27.33 |
| Percent B (%b) | 0.03 |
| BandWidth | 27.91 |
| MACD Line | -1.97 |
| MACD Signal Line | -1.63 |
| MACD Histogram | -0.3364 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 30.07 | ||||
| Resistance 3 (R3) | 30.33 | 29.76 | 29.66 | ||
| Resistance 2 (R2) | 29.76 | 29.14 | 29.64 | 29.52 | |
| Resistance 1 (R1) | 28.69 | 28.75 | 28.41 | 28.43 | 29.39 |
| Pivot Point | 28.12 | 28.12 | 27.98 | 28.00 | 28.12 |
| Support 1 (S1) | 27.05 | 27.50 | 26.77 | 26.79 | 25.83 |
| Support 2 (S2) | 26.48 | 27.11 | 26.36 | 25.70 | |
| Support 3 (S3) | 25.41 | 26.48 | 25.56 | ||
| Support 4 (S4) | 25.15 |
